Novartis Arthritis Drug Falls Short in Challenge to Global Bestseller Novartis Arthritis Drug Falls Short in Challenge to Global Bestseller

Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug Cosentyx (secukinumab) can beat the world ' s best-selling drug Humira (adalimumab) in treating a type of arthritis.Reuters Health Information
Source: Medscape Orthopaedics Headlines - Category: Orthopaedics Tags: Rheumatology News Source Type: news